9 Meters Biopharma, Inc. (NMTR)
| Market Cap | 377.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -63.32M |
| Shares Out | 211.28M |
| EPS (ttm) | -0.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 16 |
| Last Price | $1.42 |
| Previous Close | $1.44 |
| Change ($) | -0.03 |
| Change (%) | -1.74% |
| Day's Open | 1.43 |
| Day's Range | 1.38 - 1.45 |
| Day's Volume | 785,324 |
| 52-Week Range | 0.45 - 2.26 |
Initiating the largest Phase 2 placebo-controlled trial in short bowel syndrome Topline results of the multicenter VIBRANT study anticipated in Q4 2021 RALEIGH, NC / ACCESSWIRE / June 14, 2021 / 9 Meter...
RALEIGH, NC / ACCESSWIRE / June 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO o...
RALEIGH, NC / ACCESSWIRE / June 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO o...
- Larazotide supplied to study authors under an FDA-approved Expanded Access Program - - Treatment showed a dramatic drop in inflammatory mediators leading to clinical stabilization, providing proof-of-...
Investors need to pay close attention to 9 Meters Biopharma (NMTR) stock based on the movements in the options market lately.
This version of the release contains a corrected hyperlink. RALEIGH, NC / ACCESSWIRE / May 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in ...
RALEIGH, NC / ACCESSWIRE / May 18, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, Jo...
RALEIGH, NC / ACCESSWIRE / May 17, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today that the Uni...
9 Meters Biopharma Provides Business Update and Reports Financial Results for the First Quarter 2021
- Company Closed a $31.5M equity offering in April 2021; provides cash runway into 2023 - Plan to initiate Phase 2 trial with NM-002 in SBS with total stool output as the primary endpoint in Q2 followin...
RALEIGH, NC / ACCESSWIRE / April 21, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that management will par...
Penny stocks continue to trend; which should you add to your watchlist? The post 3 Penny Stocks For Your ‘Doge Day' Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt...
RALEIGH, NC / ACCESSWIRE / April 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will en...
RALEIGH, NC / ACCESSWIRE / April 12, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will co...
Some of the company's executives are making notable moves.
RALEIGH, NC / ACCESSWIRE / April 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the closing of its previo...
RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the pricing of an underw...
RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that it has commenced a ...
FDA Type C meeting communications support plans to initiate Phase 2 in Q2 with NM-002 for short bowel syndrome (SBS) using Total Stool Output (TSO) as a primary efficacy outcome measure Announced posit...
Tuesday, March 23rd @ 11am Eastern Time RALEIGH, NC / ACCESSWIRE / March 15, 2021 / 9 Meters Biopharma (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announ...
- Oppenheimer 31st Annual Healthcare Conference - March 16th - 18th - Maxim Group 2021 Emerging Growth Virtual Conference - March 17th - 18th RALEIGH, NC / ACCESSWIRE / March 10, 2021 / 9 Meters Biophar...
RALEIGH, NC / ACCESSWIRE / March 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today that chief medical officer Patr...
RALEIGH, NC / ACCESSWIRE / March 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the Company has appointed Micha...
9 Meters Biopharma (NMTR) has moved higher as of late, but there could definitely be trouble on the horizon for this company.
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
NMTR stock is on the move Wednesday. Here's what you should know about 9 Meters Biopharma, which specializes in GI conditions.
Larazotide, a novel tight junction modulator, has shown positive effect in multiple lung models of acute respiratory distress, acute lung injury, and pulmonary fibrosis with potential effects in COVID-1...
9 Meters Biopharma (NMTR) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Investors need to pay close attention to 9 Meters Biopharma (NMTR) stock based on the movements in the options market lately.
9 Meters Biopharma (NMTR) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Shares of 9 Meters Biopharma Inc (NASDAQ: NMTR) were ripping higher following a bullish initiation by Brookline Capital Markets.
NEW YORK, July 13, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cl...
9 Meters Biopharma Inc. (NASDAQ: NMTR) may not be a household name right now, but one brokerage firm sees huge potential upside.
About NMTR
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on patients with rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease, as well as for undisclosed rare diseases and/or unmet needs. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease; and NM-002, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that is in Phase 2 clinical trial to treat SBS. It al... [Read more...]
| Industry Biotechnology | Founded 2012 |
| CEO Sandeep Laumas | Employees 12 |
| Stock Exchange NASDAQ | Ticker Symbol NMTR |